甲状腺肿瘤术前TERT启动子突变单独或合并其他突变的疾病特异性与组织学结局
该回顾性单中心研究纳入术前细针穿刺检出TERT启动子突变(C228T/C250T)的70个甲状腺结节,其中18个(26%)为单独TERT突变,52个(74%)合并至少一种其他突变。结果显示,TERT合并其他突变者恶性率(96%)高于单独TERT者(67%),但低分化或未分化癌在两组中比例相当(33%)。
要点
- 术前检出TERT启动子突变者恶性风险高达93%,应积极考虑手术。
- 单独TERT突变结节中Bethesda III/IV细胞学更常见(94% vs 56%)。
- TERT合并其他突变时恶性率更高,倾向行甲状腺全切除术。
核心结论
- 术前检出TERT启动子突变与极高的恶性风险(93%)相关,且约1/3为低分化或未分化癌,单独或合并其他突变时该风险相当。
- 单独TERT突变结节应强烈考虑手术,合并其他突变时倾向于甲状腺全切除术。
研究设计与样本
- 回顾性单中心研究,纳入所有接受初始诊断性甲状腺结节评估、术前细针穿刺样本经TSv3检测发现TERT启动子突变(C228T/C250T)的成年患者,共70个结节。
主要发现
- 70个结节中18个(26%)为单独TERT突变,52个(74%)合并至少一种其他突变。
- 最常见合并异常为BRAFV600E(23个,44%)、RAS(19个,37%)和拷贝数变异(CNA;15个,29%)。
- 单独TERT突变患者年龄大于合并突变者(p=0.007),结节平均大小3.2 cm,两组相似(p=0.18)。
- 单独TERT突变组Bethesda III/IV细胞学比例更高(94% vs 合并突变组56%,p=0.007)。
- 有组织学结果的结节中,合并突变组恶性率96%高于单独TERT组67%(p=0.02),低分化或未分化癌占恶性肿瘤的33%,两组比例相当。
临床怎么用
- 术前检出TERT启动子突变应视为高恶性风险标志,强烈考虑手术。
- 单独TERT突变结节建议积极手术,合并其他突变时倾向甲状腺全切除术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: TERT promoter mutations in thyroid cancer are associated with aggressive disease, including recurrence, distant metastasis, and disease-related mortality. We aim to assess histological and disease-related outcomes when TERT mutation is detected alone or with other alterations during preoperative testing. Methods: A retrospective, single-institution study was performed, including all adult patients undergoing initial diagnostic thyroid nodule evaluation with TERT promoter mutation (C228T/C250T) detected in preoperative thyroid fine needle aspiration samples using TSv3 testing. Results: Of 70 thyroid nodules, 18 (26%) were isolated (iTERT), and 52 (74%) were associated with ≥1 concurrently detected mutation (TERT+). The most common additional abnormalities were BRAFV600E (23, 44%), RAS (19, 37%), and copy number alterations (CNA; 15, 29%). Patients with iTERT were older than those with TERT+ nodules (p = 0.007). While nodule size was similar between the two groups (mean size 3.2 cm, p = 0.18), Bethesda III/IV cytology was more likely with iTERT (94% vs. Bethesda V/VI 56%, p = 0.007). Histology was available for 9 (50%) iTERT and 51 (98%) TERT+ nodules and malignancy was higher with preoperative detection of TERT+ compared with iTERT (96% vs. 67%, p = 0.02). Poorly differentiated or anaplastic cancers were diagnosed in 33% of the malignancies at an equivalent rate in both cohorts. At median follow-up of 13.1 months (interquartile range 26.2, 7.2-33.4), distant metastasis occurred in 32.7% of patients including 17% (1/6) with iTERT versus 33% of patients with TERT+ (p = 0.65). None of the iTERT patients had locoregional recurrence as compared with 25% of TERT+ patients (p = 0.31). Conclusions: When preoperatively detected, TERT promoter mutations are more often seen in association with additional driver mutations or other genetic alterations such as CNA, but when present, carries a very high risk of malignancy (93%). Up to 1/3 are poorly differentiated or anaplastic thyroid cancer, and this likelihood is equivalent when TERT is present in isolation or in combination with other mutation. Thus, surgery should be strongly considered in iTERT nodules, and total thyroidectomy should be favored when TERT+ is identified.
引用
- Calcaterra M, Sada A, Karslioglu-French E, et al. Disease-Specific and Histological Outcomes of Preoperative TERT Promoter Mutation Detected in Isolation or in Combination with Other Mutations in Thyroid Neoplasms. Thyroid. 2025. PMID: 40833815. doi:10.1177/10507256251370304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。